Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Clinical evidence

MM-120-101

33 evidence topics · 7 sources

Objective
Location and study date
Registry record
ItemRegistry record
Scientific title“Phase I trial: MM-120-101”
IRAS number“1007602”
Sponsor“Mind Medicine Inc”
Countries of recruitment“United Kingdom”
Participating centre“MAC Clinical Research Liverpool”
Participating centre“MAC Clinical Research Manchester”
Date of first enrolment“13/10/2023”
Date of final enrolment“04/12/2023”
Completion date“19/12/2023”
Overall study status“Deferred”
Study design
Registry design description
ItemRegistry record
Study design“Phase 1 study in 30 healthy volunteers”
Primary study design“Other”
Phase“Phase I”
Intervention type“Drug”
Eligibility criteria
Registry eligibility fields
ItemRegistry record
Participant type“Healthy volunteer”
Age group“Adult”
Sex“All”
Health condition studied“Healthy volunteers”
Treatment
Study outcomes
Rationale for using plasma pharmacokinetic parameters as the primary endpoint

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size
ItemRegistry record
Target sample size at registration“30”
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Pharmacokinetic parameters by formulation
PK parameterMM120 capsuleMM120 ODT
Tmax (hr)“2.25”“2.0”
Cmax (ng/mL)“2.63”“2.68”
AUC0-∞ (ng*hr/mL)“15.7”“18.7”
AUC>1ng/mL (ng*hr/mL)“9.7”“12.0”
Geometric mean ratios relative to the capsule
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events in the pooled safety poster
MeasurePhase 1 PK bioavailability study, DT120 ODT (n = 29)
Any TEAE“25 (86.2)”
Mild“15 (51.7)”
Moderate“9 (31.0)”
Severe“1 (3.4)”
Study limitations
Summary

MM-120-101 was an open-label, randomized, two-period crossover study in healthy adults aged 18 to 55 years; it measured plasma pharmacokinetics, subjective effects, and adverse events, and enrolled no participants with GAD. Of 30 planned participants, 29 were randomized and 24 received both formulations; the pharmacokinetic analysis used those 24. Each formulation was given once at 100 µg, so the study does not inform repeated dosing or other dose levels.

Results come from an abstract, company presentations, and a safety analysis across four DT120 studies; publication of the registry record's full details is deferred to 19/12/2028. Sources differ on the pharmacokinetic summary: the abstract reports Cmax as similar, an AUC geometric mean ratio 16% higher with the ODT, and bioavailability similar to the capsule, while a company presentation describes 17% improved bioavailability (a geometric mean ratio of 1.17), a 23% increase in AUC at target concentration, and reduced gastrointestinal side effects based on a comparison between the phase 2b capsule study and this study. Sources also differ on adverse events with the ODT: the abstract reports 23 participants (79.3%) with TEAEs after the ODT, and the pooled safety poster reports 25 (86.2%) in a column labeled DT120 ODT (n = 29). The company's annual report states that the bridging study was completed in 2024, while the registry gives a completion date of 19/12/2023. The annual report states that the change in formulation could cause the product to perform differently, and one author names formulation bridging among the conditions on which adoption will depend.